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Introduction
Based on the success of cisplatin, platinum-based drugs remain the first line of treatment -either alone or in combination with other anticancer drugs -for a variety of cancers, including head and neck, testicular and ovarian. [1] One of the targets of cisplatin is DNA, where -following ligand substitution -the molecule binds irreversibly to the nucleobases, typically at N7 sites of guanine, creating both intra and inter-strand cross-links. [2] Since the cellular DNA mismatch repair or nucleotide excision repair systems do not process these lesions efficiently, an apoptotic cell death response is induced. [3] Despite the success of cisplatin, intrinsic or acquired drug resistance combined with toxicity represents a significant challenge for the future of platinum chemotherapy. [4] Mechanisms that contribute to platinum-based resistance include changes in efficiency of drug accumulation, intra-cellular thiol levels and DNA adduct repair, [4] with resistance often being multifactorial. Such resistance requires ever-greater doses of platinum therapeutic, eventually precluding safe use of the drug due to the inherent high toxicity of the molecule.
One strategy to overcome this problem has involved the design of new transition metal-based compounds, which aim to utilise the opportunities afforded by co-ordination chemistry to explore novel chemical space in cancer biology. Specifically, by employing a variety of metal centres, the effect of ancillary and active ligand(s) on reactivity, cellular uptake and antiproliferative potency has been explored in detail. [5] With some exceptions, [6] work in this area has often focussed on the development of potent, purely cytotoxic systems. However, clinical application of cytotoxic drugs is often restricted by narrow therapeutic windows and inherent off-target tissue toxicity. [7] This principle may be illustrated by platinum-based drugs themselves: carboplatin, a less potent cisplatin-derivative, was introduced in an attempt to reduce the nephrotoxicity and emetic properties of the parent complex, [1] while clinical trials of the highly cytotoxic trisplatinum agent BBR 3464 ceased due to its severe dose-limiting side-effects. [8] As insights into the cell biology of cancer have developed, targeted therapy has emerged as an alternative approach to conventional cytotoxic chemotherapy.
[9] Utilising a detailed understanding of the molecular aetiology of individual tumours, targeted therapies aim to inhibit the growth and spread of cancer either by selectively down-regulating intra-cellular pathways on which specific cancers have become dependent, [10] and /or by re-activating tumour-suppressor pathways that have been downregulated in a tumour. [11] Much current targeted therapy development has focused on use of cytostatic therapeutics [12] to halt cell proliferation by modulating molecular components, currently most often growth factor receptors, involved in cell cycle progression and consequently proliferation. Targeted therapeutics include, but are not restricted to, signal transduction inhibitors that interfere with the transition from G1 to S phase, blocking cellular signalling pathways that regulate this cell cycle progression known as the restriction point. The normal function of the restriction point is to ensure that, in the absence of appropriate extra-cellular proliferative cues, the cyclin-dependent kinase cyclin D/Cdk4 is not activated, preventing cell cycle progression and proliferation. [13] An example of a clinically relevant targeted therapeutic is the monoclonal antibody trastuzumab (Herceptin), which suppresses growth of relevant (Her2 + ) human breast cancers by interfering with the receptor tyrosine kinase HER2. [14] Further clinical examples include the combinational therapy drug Lapatinib (Tyverb, GW572016), a dual inhibitor of the epidermal growth factor (EGF) and HER2 receptor tyrosine kinases [15] , as well as the small molecule Tamoxifen which, in active form, antagonises the activation of estrogen receptors (ER) by estrogen in ER-positive breast cancer cells. [15a, 16] Tamoxifen is a very effective primary treatment, in pre-and post-menopausal women, as well as in the metastatic setting for tumours that express the estrogen receptor, [17] despite the fact that in relevant cells it is not especially potent, with a reported half inhibitory concentration, IC50, of 27 M. [18] In all cases, these therapeutic approaches have the effect of preventing cyclin D/Cdk4 activation to bring about cytostatic G1 arrest. However, therapeutic efficacy in prevention of cyclin D/Cdk4 activation requires significant levels of the cyclindependent kinase inhibitor, p27 KIP1 , [19] a tumour suppressor that binds to and inactivates the kinase. While not mutated in cancer, p27 KIP1 levels are frequently down-regulated in multiple cancer types. [13] Clearly then, there is significant unmet need for novel therapeutics that up-regulate p27 KIP1 function to induce growth arrest in human cancers, not least where the targeted therapeutics above are clinically indicated, [15a, 16] but potentially also where signal transduction targets have yet to be identified, as in so-called "triple-negative' breast and ovarian cancers. [20] Herein, we report the synthesis, DNA-binding properties, and anticancer activity of a new Ru 
Results

Synthesis and characterization
The monometallic Ru II complex VR52 and bimetallic Ru II -Pt II polypyridyl complex VR54 were synthesized through the route shown in Scheme 2. This synthetic pathway involves the preparation of the precursor complex [Ru(tpy)(tpy-a)] 2+ (tpy = 2,2':6',2''-terpyridine; tpy-a = 4-([β,β :6 ,β -terpyridine]-4yl-)aniline), [21] followed by conversion of tpy-a to the ditopic ligand [23] while the single 195 Pt resonance observed at -2967 ppm is in good agreement with structurally related Pt II compounds. [24] Likewise for VR63, a single 195 Pt resonance is observed at -3142 ppm. Based on trans effects, we assign the DMSO ligand to the trans-position with respects to the pyridin-2-yl-methyl coordination site of the tpypma or amp ligands for VR54 and VR63 respectively. The UV-visible absorption spectra of VR52, VR54 and VR63 are summarized in Table 1 . Through comparison with related molecules, [21] bands centred at approximately 273 nm and 309 nm for complexes VR52 and VR54 were assigned to intra-and inter-ligand electronic transitions. The visible region is dominated by broad (Ru(d)tpy/tpypma(*)- ), corresponding to aromatic intra-ligand electronic transitions. As is common for Ru(tpy)2 derivatives, [25] VR52 and VR54 demonstrated negligible luminescence upon MLCT excitation and are virtually non-emissive.
Scheme 2. Synthesis of VR52 and VR54. -terpyridyl complexes. [29] Cisplatin has previously been shown to possess a high affinity for guanine, where specifically the platinum(II) centre coordinates to the N7 position after chloride ligand(s) substitution. [2] Reactions with guanine derivatives such as guanosine are therefore commonly employed to assess whether platinum-containing drug candidates can bind DNA irreversibly. [30] Figure 2a , the addition of cisplatin to guanosine results in a decrease in the intensity of the H8 guanosine resonance at 8.10 ppm, accompanied by the appearance of two new resonance peaks at 8.51 and 8.63 ppm (Figure 2a ), which increase in magnitude with exposure time. Likewise, a decrease in the H2 guanosine resonance at 5.95 ppm and corresponding appearance of the downfield-shifted peak at 6.10 ppm is observed (Figure 2a ). This expected behaviour confirms that cisplatin binds guanosine via direct coordination (platination) of the Pt II metal centre to the N7 position of guanosine.
[30b] Similarly, addition of VR63 to guanosine resulted in rapid loss of H8 guanosine resonance and the appearance of two new resonance peaks at ~9.0ppm, which is also consistent with the notion that VR63 interacts with this nucleobase via N7 platination ( Figure 2b ).
In contrast to the behaviour demonstrated by cisplatin and VR63, no evidence of any effect on the NMR spectra of guanosine was observed following addition of VR54 (Figure 2c 
Impact on cancer cell proliferation
As discussed, both drug-resistance, in addition to the absence of identified specific targets in particular cancers, represents a significant on-going challenge for chemotherapy. Therefore, the effect of VR54 on the proliferation of cisplatin-resistant, A2780CIS ovarian cancer cells was investigated. Quantitative analysis of cell numbers over time in the presence of VR54 indicated a dose-dependent decrease in proliferation with a half inhibitory concentration (IC50, defined as the concentration resulting in 50% reduction in the fold extent of proliferation) of ~40 µM after 48 h exposure (Figure 3a) . Interestingly, negligible signs of cell stress or death were observed, even at higher concentrations of VR54 (Figure 3b ). Importantly, although cell proliferation was significantly affected by VR54, the viability of cells (proportion of cells that exclude Trypan-blue) exposed to active doses (40-100 µM) remained unchanged ( Figure 3b , and see below, Figure 6 ); cells numbers reached a plateau after ~48h, behaviour which implies cytostatic activity. In contrast, cell numbers in samples treated with cisplatin progressively decreased until cells numbers were negligible; as expected for cytotoxic activity (Figure 3a -see cisplatin data).
To provide an indication of the anti-proliferative capability of VR54 towards a cisplatin-sensitive line compared to resistant cells, a direct comparison between parental (cisplatin-sensitive) A2780 and derivative (cisplatin-resistant) A2780CIS cells was undertaken using a complementary approach. Cells were exposed to a range of concentrations of VR54 or cisplatin for 48 h and the resultant metabolic activity of each cell population was assessed using
[31] The mononuclear Ru II parent complex VR52 and mononuclear Pt II complex VR63 were included in parallel to provide information on the structural properties required for the potency of VR54 ( Figure S12 ). As shown in Figure 3c and Table 2 , these experiments confirm the impact of VR54 on cell proliferation, and are consistent with the IC50 value for VR54 determined by analysis of cell numbers in A2780CIS cells after 48h exposure as determined above. As expected, [32] a ten-fold decrease in potency was observed in A2780CIS cells treated with cisplatin compared with the parental line ( Figure 3d and Table 2 ). Significantly, and in direct contrast to results obtained with cisplatin, no crossresistance to VR54 was observed ( Figure 3c ), with potency of VR54 almost identical in both cisplatin-sensitive and cisplatinresistant ovarian cancer cell lines (IC50 of 29 and 38 µM for A2780 and A2780CIS cells respectively). The mononuclear Ru II analogue VR52 had negligible effects on either cell line, while the mononuclear Pt II complex VR63 exhibited a four-fold lower potency towards A2780 cells (IC50 = 114 µM) and had no impact upon A2780CIS cell numbers/viability in the concentration range tested (Table 2 and Figure S12 ). These results indicate that both the Ru II structural moiety and Pt II metal centre are required for the anti-proliferative behaviour demonstrated by VR54. Table 2 for details on the IC50 values. Table 2 . Anti-proliferative capability (IC50, (µM) defined as the concentration resulting in 50% reduction in the metabolic activity of the total cell population remaining after the indicated incubation period) of VR52, VR54, VR63 and cisplatin towards A2780 and A2780CIS human ovarian cancer cells. [a] Determined by MTT assay (48 h incubation time). Data average of three independent experiments ± SD. See note [31] .
Cellular uptake properties
It is well established that the internalization characteristics of metal anticancer complexes may contribute to their efficacy. [1, [3] [4] Given that VR54 has a significantly greater impact on cell proliferation compared to either mononuclear complexes VR52 or VR63, we therefore investigated whether the extent of cellular uptake could explain the difference in bioactivity of each complex.
The relative cellular accumulation of all three compounds in A2780CIS cells was determined using inductively-coupled plasma mass spectrometry (ICP-MS). For cells incubated with solutions of VR52, VR54, VR63 or cisplatin prior to analysis, the levels of Ru and/or Pt above an untreated control therefore correspond to the cellular accumulation of the relevant complex. As VR54 is a Ru Figure S13 ). Therefore, we cannot exclude the possibility of complex fragmentation upon cellular internalisation, and that VR54 might function as a prodrug. These results also clearly indicate a greater cellular accumulation of the binuclear conjugate complex VR54 than either mononuclear complexes VR52 or VR63, where data indicate five-fold lower levels of Ru metal ion content for cells incubated with VR52 (VR52 = 0.37 ± 0.03 fmoles Ru/cell) and a 2.5-fold lower Pt content for VR63 (0.58 ± 0.10 fmoles Pt/cell) compared to the results for VR54 (Figure 4 ). Subsequently normalising these ICP-MS data to cellular protein content ( Figure S14 ), it is clear that VR54, and even the poorly-active VR52, both demonstrate a greater degree of internalisation than certain cytotoxic Ru II polypyridyl DNA intercalators. [35] The relationship between an increase in hydrophobicity and extent of cellular uptake of metal complexes has been demonstrated for a range of metal compounds. [36] In agreement with this concept, the relative cellular uptake levels of VR54, VR52 and VR63, and their anticancer potency, correlate with the hydrophobicity of each complex, as quantified by octanol/water partition coefficient, log P (Figure 4 ). Despite this clear trend, it is apparent that VR63, which has a comparable log P to cisplatin, has a lower level of cellular uptake -and corresponding decrease in potency -than would be predicted if hydrophobicity were the sole factor in governing internalisation.
To examine the sub-cellular localisation of VR54, A2780 cells were incubated with the complex and cell fractions from the resultant lysates were prepared. The Ru and Pt content in all fractions (nuclear-, mitochondrial-and cytosolic-enriched fractions) were then analysed by ICP-MS. These data show a high proportion of both Pt and Ru content in the nuclear fraction ( Figure S15a) . However, upon normalization to protein content of each fraction, it is clear that accumulation of both metals is relatively consistent across these intracellular compartments with a small degree of enrichment (amount of metal/protein per subcellular fraction divided by amount of metal/protein in total cell lysate -see reference [37] ) in the mitochondrial and (for Ru) nuclear fractions ( Figure S15b ). The differences in the proportions of Ru and Pt in each subcellular fraction again indicates that we cannot exclude the possibility of intracellular fragmentation, and some degree of differential accumulation within distinct cell compartments. 
VR54 does not induce apoptosis or necrosis
The intra-strand and inter-strand crosslinks arising from exposure to cisplatin and derivatives activate several DNA damage signalling pathways that ultimately culminate in apoptosis. [1, [3] [4] Therefore, as a starting point to elucidate the cellular mechanism of action of VR54, relative levels of apoptosis after exposure to active doses of the Ru II -Pt II complex were characterised. Firstly, cells were incubated with either VR54 or cisplatin at their respective IC50 concentrations for up to 48 h and the extent of pyknosis and/or karyorrhexis, typical indicators of late-stage apoptosis, was determined. In addition, lysates derived from treated cells were immunoblotted for the active (cleaved) form of the apoptotic marker, caspase-3. Figure  5a shows that, as expected on cisplatin treatment, the fraction of cells with observable nuclear fragmentation increased with time and accounted for over 35 % of cells remaining after 48 h. In contrast, cells incubated with VR54 showed minimal (< 1 %) evidence of chromatin abnormality. Consistent with this, cells treated with the IC50 concentration of cisplatin contained significant levels of activated caspase-3 after 24 h, which continued to increase with time of exposure; clearly indicating an apoptotic response (Figure 5b ). In contrast to cisplatin treatment, no activation of caspase-3 was observed in cells treated with an equipotent dose of VR54 (Figure 5b ). These results indicate that exposure to anti-proliferative doses of VR54 does not result in significant levels of apoptosis in A2780CIS cells. In the absence of an apoptotic response to VR54, we next characterised the levels of total cell death, independent of pathway. To achieve this, A2780CIS cells were treated with antiproliferative doses of VR54 and the number of Trypan bluepositive (membrane-compromised) cells quantified. While not able to discriminate between cell death pathways, this assay will quantify levels of secondary necrosis, i.e. cells which have lost plasma membrane integrity. Once more, cisplatin was used in parallel as a cytotoxic control. Trypan-blue staining revealed exposure of A2780CIS cells to VR54 did not result in the generation of significant levels of membrane-compromised necrotic cells above an untreated control: treatment with the IC50 concentration (determined as described in Table 2 ) of 40 µM VR54 resulted in 4 % necrosis and even at doses of 100 µM VR54 less than 6 % of the cell population has undergone secondary necrosis (Figure 6 ). Each of these values is comparable to background levels of 3 % Trypan-blue positive cells obtained for untreated control cells. In contrast, exposure to cisplatin generates a large proportion of membranecompromised cells, where 18 % secondary necrosis is observed for cells treated with the IC50 concentration and the levels of non-viable cells approach 40 % for cells treated with 100 µM cisplatin; clearly indicating high levels of cell death due to treatment with the cytotoxic compound.
These data provide compelling evidence that VR54 inhibits the proliferation of cancer cells without inducing significant levels of cell death. Thus, we conclude VR54 is predominantly acting in a cytostatic, rather than cytotoxic, capacity. 
VR54 induces G1 cell cycle arrest
As VR54 exerts an anti-proliferative effect by inducing cytostasis, we hypothesised that cell cycle arrest could explain the inhibition of cell growth by the complex. To explore the effect of VR54 on the cell cycle, cells were either untreated or exposed to VR54 for 24 h before fixation and flow cytometric analyses. The percentage of cells within each phase of the cell cycle was determined by propidium iodide (PI) staining and DNA content quantification. Figure 7 shows that treatment of cycling A2780CIS cells with 40 µM VR54 results in a significant concentration-dependent increase in cells in G1 phase compared to the control (65.3 % of the total population in G1 versus 42.7 % respectively), a dramatic apparent reduction in the proportion of S-phase cells (25.5 % versus 42.1 %), and concomitant decrease in the proportion of cells in G2/M phase (9.2 % versus 15.2 %). The higher dose of VR54 (100 µM) results in an approximately two-fold increase in G1 phase cells (78.9 %) compared to the untreated control ( Figure 7) . Consistent with the low levels of apoptotic markers described in Figure 5 above, there was no sub-G1 (apoptotic) population in cells treated with VR54.
The large increase in G1 phase cells upon VR54 treatment indicates VR54 inhibits cell proliferation through impeding cell cycle progress, either by inducing cell cycle arrest during G1 phase or by inhibiting the transition from G1 to S phase. 
VR54 does not activate the DNA damage response network
We next set out to elucidate the molecular mechanism responsible for VR54-induced cell cycle arrest. Since cell cycle checkpoints modulate DNA damage/genome integrity responses by controlling the timing of cell cycle progression, and univariate cytometric analyses cannot easily distinguish between cells arrested in G1 or in early S phase, we examined whether VR54-induced cell cycle arrest occurs via activation of DNA damage signalling pathways. Therefore the status of both ATR/Chk1 and ATM/Chk2 checkpoint signalling pathways, which are activated primarily in response to replication stress and double-strand breaks respectively, [38] was examined. Pathway activation was assessed by determining the extent of phosphorylation of both Chk1 and Chk2 using phospho-specific and total protein antibodies that recognize activated, and all forms of each protein, respectively. Furthermore, the levels of the phosphorylated form of the checkpoint regulator, p53, and a proxy marker of DNA double-strand breaks, phospho-histone H2AX ( -H2AX), were also determined. As Figure 8 shows, there was no increase in phospho-Chk1 (Ser345) levels in cells treated with VR54 compared to an untreated (-ve) control. In stark contrast, cells incubated with cisplatin exhibited a progressive, time-dependent increase in Chk1 activation, presumably due to replication stress caused by the presence of cisplatin-induced lesions. Similarly, cisplatin, but not VR54, induced significant time-dependent activation of Chk2 (phospho-Chk2, Ser516), as well as an increase in phospho-H2AX (Ser139) and phospho-p53 (Ser10). Again this observation is consistent with the expected generation of cisplatin mediated inter-strand crosslinking, resulting in double-strand breaks and a consequent cellular DNA damage response. These data indicate that treatment of A2780CIS cells with VR54 does not activate the DNA damage response signalling network, providing confirmation that the cytostatic VR54 operates via a cellular mechanism of action distinct from that of cisplatin. 
VR54 up-regulates p27 and inhibits Rb phosphorylation
The transition from G1 to S phase is mediated by activation of cyclin D-Cdk4/6 and cyclin E-Cdk2 protein kinases. [39] Cdks may be inhibited by specific cyclin-dependent kinase inhibitors (CKIs) such as p21 CIP1 and p27 KIP1 , and increased levels of either can result in failure to progress from G1 into S-phase. The former is frequently up-regulated in a p53-dependent manner as part of the DNA damage response. [40] External signals predominantly modulate p27 KIP1 levels, with serum deprivation and contact inhibition resulting in its up-regulation, and serum addition or growth factors inducing its down-regulation. [41] As indicated above, exposure to VR54 results in significant G1/S cell cycle arrest. In the absence of evidence of p53 activation (Figure 8 , lower panels), we investigated whether VR54 acts through the up-regulation of the G1 Cdk inhibitor, p27 KIP1 by determining levels of p27 KIP1 expression as a result of treatment with VR54.
Serum starvation was used as a positive control for upregulation of p27 KIP1 . [41] Western blot analysis of A2780CIS cells treated with VR54 for 24 h showed a significant dose-dependent increase in the levels of p27 KIP1 compared to an untreated control (Figure 9a , upper and lower panels). Quantifying this increase, treatment of cells with 40 µM VR54 resulted in a ~ 2-fold increase in p27 KIP1 levels, while cells exposed to 100 µM VR54 resulted in levels of p27 KIP1 significantly greater than observed in serum-starved (i.e. quiescent) cells, a four-fold increase compared to the (serumcontaining) untreated control (Figure 9a , lower panels). p27 levels in cells treated with 100 µM VR52 or VR63 showed comparable p27 KIP1 levels to the untreated control, consistent with the absence of an effect of either mononuclear complex on cell proliferation at these concentrations. The increased p27 KIP1 levels arising from exposure to VR54 directly correlate with the inhibition of cell growth and cell cycle accumulation in G1 phase. In order to confirm that VR54 exerts its cell cycle inhibitory effect via up-regulation of p27 KIP1 and consequent inhibition of cyclin-Cdk complexes, we examined the effect of VR54 on the activation status of the tumour suppressor retinoblastoma protein (Rb), which plays a key role in the exit from G1 phase. [13] During the progression from G1 into S phase, active hypophosphorylated Rb is deactivated via phosphorylation by the cyclin D-Cdk4/6 and cyclin E-Cdk2 kinases to facilitate cell cycle progression. [42] Using antibodies that recognize either phosphorylated Rb (at Ser780) or total Rb levels, we examined the phosphorylation status of Rb in VR54-treated cells by western blot analysis to determine the activation status of this pathway. Figure 9b (upper panel) shows cells exposed to VR54 exhibit a progressive, concentration-dependent decrease in levels of p-Rb phosphorylated at Ser 780, indicating the strong inhibition of Rb phosphorylation at this site. Consistent with this observation, the ratio of hyper-phorylated Rb to hypophosphorylated Rb decreased with exposure to VR54 (Figure 9b , middle panel). These results indicate the phosphorylation of Rb is dramatically inhibited by VR54 and are in agreement with the concept that VR54 up-regulates p27 KIP1 . In order to investigate any contribution of p21 to the hypophosphorylation of Rb, we undertook western blot analysis of p21 levels following exposure to VR54, however, no increase in p21 was observed after 24 h exposure ( Figure S16 ). We therefore conclude that the mechanism of action of VR54 is through the up-regulation of p27 KIP1 and resultant inhibition of Rb phosphorylation. The inhibition of Rb phosphorylation acts to block cell cycle entry into S phase at the G1 restriction point, culminating in G1 cell cycle arrest and the inhibition of cell growth (Scheme 3). 
Discussion
While numerous anticancer metal complexes suitable for conventional cytotoxic chemotherapy have been described, metal compounds that inhibit cancer cell proliferation by alternative modes of action have been neglected. In particular, the role of cytostatic metal complexes that interfere with cancer cell cycle regulatory pathways to halt cell growth is an unexplored area of study.
In this study, we prepared the Ru (Figure 1 ). Somewhat unexpectedly, VR54 does not bind covalently to guanosine, unlike cisplatin (Figure 2c ). It is known that DMSO substitution in solution decreases the activity of cisplatin, [43] while a similar lack of reactivity towards nucleotide coordination has been observed for several Pt II (Cl)(DMSO) complexes. [44] However, DMSO substitution alone cannot explain the lack of reactivity of VR54, as significant reactivity was observed with VR63 ( Figure 2b) . Thus, the lack of reactivity of VR54 towards guanosine is likely due to a combination of DMSO substitution and the electronwithdrawing properties of the attached Ru II -tpypma complex. Our cellular studies nonetheless show VR54 inhibits the proliferation of A2780 ovarian cancer cells and, importantly, the potency of its anti-proliferative effect observed is retained in cisplatin-resistant A2780CIS cells (Figure 3) . In either case, the potency of VR54 is not substantially different from that of tamoxifen, [18] used in the treatment of estrogen receptor+ breast tumours. These data suggest that there is potential for future design and optimisation of metal complexes that are potently anti-proliferative, but are not subject to the some of the mechanisms which give rise to platinum resistance. [45] or alternatively by targeting a specific transporter protein through a recognition motif, [46] as the correlation of cellular accumulation with log P does not necessarily infer passive transport as the dominant uptake mechanism for transition metal compounds.
[47]
Several strong lines of evidence indicate that VR54 inhibits cancer cell growth via a cytostatic mechanism, and not via a cytotoxic mechanism involving the platination of nucleobases, and consequent accumulation of toxic double-strand breaks. Firstly, VR54 demonstrates a concentration dependent reduction in the rate of proliferation, but crucially in the absence of any reduction in seeded cell numbers (Figure 3a) or the appearance of any of the markers of apoptotic or other cell death (Figures 5  and 6 ). Secondly, it is well established that platinum-based drugs with labile coordination sites induce a DNA damage response involving the activation of both ATR/Chk1 and ATM/Chk2 signalling pathways following the formation of bulky inter-and intra-strand cross-links, via platination of the N7 of guanine bases. [4] Both ATM and ATR protein kinases contribute to the phosphorylation and stabilization of p53 which ultimately results in late G1/early S phase arrest and apoptosis. [48] However, no reaction was observed between VR54 and guanosine in cell-free studies, even after prolonged incubation (Figure 2 ), while, in cellular studies, VR54 did not induce histone H2AX phosphorylation, a direct marker of DNA double-strand breaks, nor did the complex have any effect on the phosphorylation state of either Chk1 or Chk2 checkpoint kinases, indicating no component of the DNA damage response pathway to be activated ( Figure 8 ). Thirdly, we found the mechanism by which VR54 inhibits proliferation of A2780CIS cells to be through a strong G1 cell cycle arrest resulting from the induction of elevated levels of the CKI, p27 KIP1 and the consequent inhibition of Rb phosphorylation (Figures 7 and 9 ). The transition from G1 into S phase, known as the restriction point, is mediated by activation of the S phase transcription factor, E2F, which binds to, and is inhibited by, hypo-phosphorylated (active) Rb. In the presence of growth factors, cyclin D-Cdk4/6 and cyclin E-Cdk2 protein kinases bring about Rb inactivation (hyper-phosphorylated Rb) which in turn releases transcriptionally active E2F, thereby ensuring the G1-S transition (Scheme 3). [13] Thus p27 KIP1 is a tumour suppressor that plays a critical role in the key regulatory system controlling cell proliferation. [19] By interfering with cyclin-Cdk mediated phosphorylation of Rb bound to E2F, p27 KIP1 prevents E2F release and therefore entry into S phase. It may be noted that the cytostatic effect of VR54 becomes apparent after ~48 h (Figure 3a) . This reflects the asynchronous nature of the cell population with respect to the cell cycle. As the intracellular concentration of VR54 builds up with resultant increases in p27 KIP1 , those cells which have passed the restriction point (late G1) are committed to undergo a round of cell division (thus increasing cell numbers), and it is only as time progresses that cells moving through the cell cycle encounter the restriction point block at the G1/S transition, resulting in overall cytostasis. Importantly, neither VR52 nor VR63 have any effect on p27 KIP1 levels, reinforcing the notion that both Ru II and Pt II components
contribute to the cellular behaviour demonstrated by VR54. Up-regulation of p27 KIP1 can be indirectly induced as a consequence of the introduction of DNA damage lesions through a p21-dependent mechanism. [49] However, since treatment with VR54 neither increases p21 levels ( Figure S16 ), nor activates p53 (Figure 8 ), a pre-requisite for the up-regulation of p21 CIP1 , [50] in response to DNA damage, we conclude VR54 cannot be upregulating p27 KIP1 either through a mechanism involving p53-mediated genomic stress induced cell-cycle arrest, or other p53 independent p21-mediated mechanisms. Furthermore, as the DNA damage response network is known to contribute in part to cisplatin-resistance, [51] it seems likely that the radically different mechanism of action of VR54 compared to cisplatin is responsible for the lack of cross-resistance towards a cisplatinresistant cell line. The cellular mechanism of VR54 has wider significance. Unsurprisingly, expression of restriction point mediators, including Rb, cyclin D, as well as p27 KIP1 itself, are frequently altered in a wide range of cancers, [13] as distortion of this regulatory system uncouples cell cycle progression from autocrine and paracrine signaling-mediated growth factor control, a key aspect of neoplastic progression. [41] As a result, the evaluation of p27 KIP1 levels are utilized to predict response to both chemotherapy and radiotherapy treatments, as well as endocrine manipulation, [52] leading to calls for the development of new therapeutics capable of p27 KIP1 up-regulation. [41] If personalized cancer therapy is to be realized, future targeted treatments, either as first line treatment or to overcome resistance, will require considerable understanding of individual cancer cell survival pathways. In this context, VR54 and derivatives may have considerable potential in association with targeted therapeutic regimes aimed at inhibiting progression through G1. For example, the effectiveness of the cytostatic drug, trastuzumab (Herceptin) in inducing cell cycle arrest in G1 phase and suppressing growth of human breast cancer depends, not only on the over-expression of the receptor tyrosine kinase HER2 in tumours, but also the presence of the cyclin-dependent kinase inhibitor protein, p27 KIP1 , to prevent the G1/S transition. [14a, 53] Similarly, tamoxifen resistance in breast cancer has been shown to involve reduced levels of p27 KIP1 , via up-regulation of miRNAs-221/222, while genetic over-expression of p27 KIP1 has been shown to restore tamoxifen resistance. [54] It follows that a combination of targeted regimens with selective chemotherapeutics may well represent an important developmental step in stratified approaches to cancer therapy. [55] Considering these points, the therapeutic application of VR54 and derivatives may involve combinatorial strategies alongside conventional targeted regimens. In such regimes, the low cytotoxicity of VR54 would be predicted to be an advantageous property.
The molecular mechanism by which VR54 up-regulates p27 KIP1 is of great interest. Cellular levels of p27 KIP1 are controlled by a highly complex multi-component network of signalling, transcriptional, translational and protein degradation pathways. [50] One intriguing possibility is that complex VR54 upregulates p27 KIP1 via subtle alteration of the cellular epigenome, either by affecting p27 KIP1 transcription directly or by altering the levels or functionality of one or more of its upstream regulators. [56] Work involving genome-wide expression profiling in the presence and absence of VR54 may be revealing in this regard.
Conclusions
In summary, we report the synthesis and characterisation of a cytostatic binuclear ruthenium(II)-platinum(II) bis(terpyridyl) complex, VR54, which inhibits the proliferation of ovarian cancer cells through the up-regulation of the cyclin-dependent kinase inhibitor p27 KIP1 , resulting in the inhibition of Rb phosphorylation and G1 cell cycle arrest. At both the molecular and cellular level, VR54 functions by a radically different mechanism to cisplatin, showing that it belongs to an entirely different category to any other platinum-based therapeutic candidate, and expands the potential scope of activity for metal-based anticancer complexes for inclusion within targeted therapy regimes.
Experimental Section Synthesis of [Ru(tpy)(tpypma)](PF6)2 (VR52).
[(tpy)Ru(tpy-a)](PF6)2 [21] (200 mg, 0.21 mmol) was dissolved in the minimum amount of dry CH3CN (1 mL) and 30 mL of dry MeOH. 2-Pyridinecarboxaldehyde (0.040 mL, 0.422 mmol) was added and the reaction mixture was refluxed for 9 h with continuous stirring. After cooling to room temperature, the solvent was evaporated under reduced pressure. The reaction mixture was re-dissolved in 100 mL of dry MeOH and refluxed for 1 h followed by the addition of excess of NaBH4 (100 mg). The reaction mixture was allowed to reflux for 3 h with continuous stirring. The reaction mixture was cooled to room temperature and 10 mL of distilled water was added to remove excess NaBH4. Saturated KPF6 (2 mL) solution was added to exchange the counter anions and the metal complex was extracted by the solvent extraction method using CH2Cl2/H2O. A minimum amount of CH3CN (0.5 mL) was added in order to bring the complex in to the organic layer from aqueous layer. This crude compound was purified by column chromatography, using silica gel as the stationary phase and CH3CN as the mobile phase. Yield: 54.7 % (120 mg, 0.115 mmol). Complex VR52 was converted to its chloride salt by anion metathesis and dried under vacuum. Potassium tetrachloro platinate (32 mg, 0.077 mmol) was dissolved in 10 mL water, followed by the addition of complex VR52 (80 mg, 0.097 mmol). The reaction mixture was stirred at room temperature (25 °C) for 3 h in the dark. The precipitate formed (VR53) was collected by centrifugation and washed with water (3 x 2 mL) to remove excess K2[PtCl4] before drying under vacuum. Yield: 64.8 % (54.5 mg, 0.050 mmol). ESIMS m/z: [M] 2+ 507.03.
Step 2 -conversion of VR53 to VR54. Complex VR53 (50 mg, 0.046 mmol) was dissolved in DMSO: H2O (1: 9). The reaction mixture was stirred at room temperature (25 °C) for 120 h in the dark. The addition of saturated KPF6 solution (1 mL) afforded a deep red coloured precipitate (complex VR54), which was collected by using grade-4 crucible followed by washing with water (3 x 2 mL). Yield: 36.9 % (26 mg, 0.017 mmol). 
Synthesis of [Pt(amp)(Cl)(DMSO)] + (VR63). [Pt(Cl)2(amp)]
[22] (100 mg, 0.26 mmol) was dissolved in DMSO: H2O (1: 9). The reaction mixture was stirred at room temperature for 2h in the dark. The addition of saturated KPF6 solution (1 mL) afforded a pale yellow coloured precipitate, which was collected by using grade-3 crucible followed by washing with water (3 x 2 mL) and diethyl ether (2 x 5 mL). Yield: 50.7 % (76 mg, 0.135 mmol). For full experimental details and protocols see supporting information.
